Review



human endometrial cancer cell lines hec 1a  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    ATCC human endometrial cancer cell lines hec 1a
    (A, B) Kaplan-Meier plots showing that LARP1 overexpression is associated with shorter overall survival (A) and progression-free interval (B) in endometrial cancer cohort (n=454). (C) Immunoblot analysis illustrating the protein expression of LARP1 after transfecting ISHI cell line with control or LARP1 siRNA at 25, 50, 75, and 100 nM. β-actin was used as a loading control. (D) Images derived from immunofluorescence analysis showing the protein expression of LARP1 after <t>transfecting</t> <t>HEC-1A</t> cells with control or LARP1 siRNA at 75 µM. Scale bar = 50 µM.
    Human Endometrial Cancer Cell Lines Hec 1a, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 205 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+endometrial+cancer+cell+lines+hec+1a/bio_rxiv__64898__2026__03__22__713473-39-0-12?v=ATCC
    Average 96 stars, based on 205 article reviews
    human endometrial cancer cell lines hec 1a - by Bioz Stars, 2026-07
    96/100 stars

    Images

    1) Product Images from "“Targeting LARP1 Enhances Carboplatin Sensitivity and Suppresses Tumor Growth in Endometrial Cancer”"

    Article Title: “Targeting LARP1 Enhances Carboplatin Sensitivity and Suppresses Tumor Growth in Endometrial Cancer”

    Journal: bioRxiv

    doi: 10.64898/2026.03.22.713473

    (A, B) Kaplan-Meier plots showing that LARP1 overexpression is associated with shorter overall survival (A) and progression-free interval (B) in endometrial cancer cohort (n=454). (C) Immunoblot analysis illustrating the protein expression of LARP1 after transfecting ISHI cell line with control or LARP1 siRNA at 25, 50, 75, and 100 nM. β-actin was used as a loading control. (D) Images derived from immunofluorescence analysis showing the protein expression of LARP1 after transfecting HEC-1A cells with control or LARP1 siRNA at 75 µM. Scale bar = 50 µM.
    Figure Legend Snippet: (A, B) Kaplan-Meier plots showing that LARP1 overexpression is associated with shorter overall survival (A) and progression-free interval (B) in endometrial cancer cohort (n=454). (C) Immunoblot analysis illustrating the protein expression of LARP1 after transfecting ISHI cell line with control or LARP1 siRNA at 25, 50, 75, and 100 nM. β-actin was used as a loading control. (D) Images derived from immunofluorescence analysis showing the protein expression of LARP1 after transfecting HEC-1A cells with control or LARP1 siRNA at 75 µM. Scale bar = 50 µM.

    Techniques Used: Over Expression, Western Blot, Expressing, Control, Derivative Assay, Immunofluorescence

    (A – D) Cell viability assay showing the effect of two different LARP1 siRNA (1 and 2) on the viability of ISHI (A, B) and HEC-1A (C, D) cell lines. One-way analysis of variance (ANOVA) was used to assess statistical significance among groups, followed by Tukey’s post hoc test for multiple pairwise comparisons. Data are presented as mean ± SD, with individual data points shown as dots. (E) Immunoblot analysis showing the protein expression of cleaved PARP1 and cleaved caspase 3 after transfection of ISHI and HEC-1A cells with control or LARP1 siRNAs. β-actin was used as a loading control.
    Figure Legend Snippet: (A – D) Cell viability assay showing the effect of two different LARP1 siRNA (1 and 2) on the viability of ISHI (A, B) and HEC-1A (C, D) cell lines. One-way analysis of variance (ANOVA) was used to assess statistical significance among groups, followed by Tukey’s post hoc test for multiple pairwise comparisons. Data are presented as mean ± SD, with individual data points shown as dots. (E) Immunoblot analysis showing the protein expression of cleaved PARP1 and cleaved caspase 3 after transfection of ISHI and HEC-1A cells with control or LARP1 siRNAs. β-actin was used as a loading control.

    Techniques Used: Viability Assay, Western Blot, Expressing, Transfection, Control

    (A, B) Immunoblot analysis showing the protein expression of LARP1 and E2F1 after transfecting ISHI (A) and HEC-1A (B) cells with control or LARP1 siRNA. β-actin was used as a loading control. (C) Images representing immunofluorescence staining of LARP1 (green) and E2F1 (red) in HEC-1A cells after transfection with control or LARP1 siRNA. DAPI was used as a counter stain. Scale bar = 50 µm.
    Figure Legend Snippet: (A, B) Immunoblot analysis showing the protein expression of LARP1 and E2F1 after transfecting ISHI (A) and HEC-1A (B) cells with control or LARP1 siRNA. β-actin was used as a loading control. (C) Images representing immunofluorescence staining of LARP1 (green) and E2F1 (red) in HEC-1A cells after transfection with control or LARP1 siRNA. DAPI was used as a counter stain. Scale bar = 50 µm.

    Techniques Used: Western Blot, Expressing, Control, Immunofluorescence, Staining, Transfection

    (A, B) MTS cell viability assay showing the effect of escalating concentration of carboplatin on the viability of ISHI (A) and HEC-1A cell lines. Sterile water was used as a vehicle control. One-way analysis of variance (ANOVA) was used to assess statistical significance among groups, followed by Tukey’s post hoc test for multiple pairwise comparisons. Data are presented as mean ± SD, with individual data points shown as dots.
    Figure Legend Snippet: (A, B) MTS cell viability assay showing the effect of escalating concentration of carboplatin on the viability of ISHI (A) and HEC-1A cell lines. Sterile water was used as a vehicle control. One-way analysis of variance (ANOVA) was used to assess statistical significance among groups, followed by Tukey’s post hoc test for multiple pairwise comparisons. Data are presented as mean ± SD, with individual data points shown as dots.

    Techniques Used: Viability Assay, Concentration Assay, Sterility, Control

    (A, C) Micrographs representing colony formation assay showing the effect of LARP1 transfection and carboplatin treatment on the clonogenic survival of ISHI (A) and HEC-1A (B) cell lines. (B, D) Quantitative analysis of clonogenic assay showing the effect of LARP1 knockdown and carboplatin treatment on the clonogenic survival of ISHI (B) and HEC-1A (D) cells. One-way analysis of variance (ANOVA) was used to assess statistical significance among groups, followed by Tukey’s post hoc test for multiple pairwise comparisons. Data are presented as mean ± SD, with individual data points shown as dots.
    Figure Legend Snippet: (A, C) Micrographs representing colony formation assay showing the effect of LARP1 transfection and carboplatin treatment on the clonogenic survival of ISHI (A) and HEC-1A (B) cell lines. (B, D) Quantitative analysis of clonogenic assay showing the effect of LARP1 knockdown and carboplatin treatment on the clonogenic survival of ISHI (B) and HEC-1A (D) cells. One-way analysis of variance (ANOVA) was used to assess statistical significance among groups, followed by Tukey’s post hoc test for multiple pairwise comparisons. Data are presented as mean ± SD, with individual data points shown as dots.

    Techniques Used: Colony Assay, Transfection, Clonogenic Assay, Knockdown



    Similar Products

    human endometrial cancer cell lines hec 1a  (ATCC)
    96
    ATCC human endometrial cancer cell lines hec 1a
    (A, B) Kaplan-Meier plots showing that LARP1 overexpression is associated with shorter overall survival (A) and progression-free interval (B) in endometrial cancer cohort (n=454). (C) Immunoblot analysis illustrating the protein expression of LARP1 after transfecting ISHI cell line with control or LARP1 siRNA at 25, 50, 75, and 100 nM. β-actin was used as a loading control. (D) Images derived from immunofluorescence analysis showing the protein expression of LARP1 after <t>transfecting</t> <t>HEC-1A</t> cells with control or LARP1 siRNA at 75 µM. Scale bar = 50 µM.
    Human Endometrial Cancer Cell Lines Hec 1a, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+endometrial+cancer+cell+lines+hec+1a/bio_rxiv__64898__2026__03__22__713473-39-0-12?v=ATCC
    Average 96 stars, based on 1 article reviews
    human endometrial cancer cell lines hec 1a - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier
    human endometrial cancer cell line hec 1a  (ATCC)
    96
    ATCC human endometrial cancer cell line hec 1a
    (A, B) Kaplan-Meier plots showing that LARP1 overexpression is associated with shorter overall survival (A) and progression-free interval (B) in endometrial cancer cohort (n=454). (C) Immunoblot analysis illustrating the protein expression of LARP1 after transfecting ISHI cell line with control or LARP1 siRNA at 25, 50, 75, and 100 nM. β-actin was used as a loading control. (D) Images derived from immunofluorescence analysis showing the protein expression of LARP1 after <t>transfecting</t> <t>HEC-1A</t> cells with control or LARP1 siRNA at 75 µM. Scale bar = 50 µM.
    Human Endometrial Cancer Cell Line Hec 1a, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+endometrial+cancer+cell+lines+hec+1a/pm40974422-46-13-23?v=ATCC
    Average 96 stars, based on 1 article reviews
    human endometrial cancer cell line hec 1a - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier
    human endometrial cancer cell lines hec-1a  (Procell Inc)
    90
    Procell Inc human endometrial cancer cell lines hec-1a
    (A, B) Kaplan-Meier plots showing that LARP1 overexpression is associated with shorter overall survival (A) and progression-free interval (B) in endometrial cancer cohort (n=454). (C) Immunoblot analysis illustrating the protein expression of LARP1 after transfecting ISHI cell line with control or LARP1 siRNA at 25, 50, 75, and 100 nM. β-actin was used as a loading control. (D) Images derived from immunofluorescence analysis showing the protein expression of LARP1 after <t>transfecting</t> <t>HEC-1A</t> cells with control or LARP1 siRNA at 75 µM. Scale bar = 50 µM.
    Human Endometrial Cancer Cell Lines Hec 1a, supplied by Procell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+endometrial+cancer+cell+lines+hec+1a/pmc11931630-51-20-32?v=Procell+Inc
    Average 90 stars, based on 1 article reviews
    human endometrial cancer cell lines hec-1a - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    human endometrioid endometrial cancer eec cell lines hec 1a  (ATCC)
    96
    ATCC human endometrioid endometrial cancer eec cell lines hec 1a
    (A, B) Kaplan-Meier plots showing that LARP1 overexpression is associated with shorter overall survival (A) and progression-free interval (B) in endometrial cancer cohort (n=454). (C) Immunoblot analysis illustrating the protein expression of LARP1 after transfecting ISHI cell line with control or LARP1 siRNA at 25, 50, 75, and 100 nM. β-actin was used as a loading control. (D) Images derived from immunofluorescence analysis showing the protein expression of LARP1 after <t>transfecting</t> <t>HEC-1A</t> cells with control or LARP1 siRNA at 75 µM. Scale bar = 50 µM.
    Human Endometrioid Endometrial Cancer Eec Cell Lines Hec 1a, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+endometrial+cancer+cell+lines+hec+1a/pm35953818-82-9-24?v=ATCC
    Average 96 stars, based on 1 article reviews
    human endometrioid endometrial cancer eec cell lines hec 1a - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    (A, B) Kaplan-Meier plots showing that LARP1 overexpression is associated with shorter overall survival (A) and progression-free interval (B) in endometrial cancer cohort (n=454). (C) Immunoblot analysis illustrating the protein expression of LARP1 after transfecting ISHI cell line with control or LARP1 siRNA at 25, 50, 75, and 100 nM. β-actin was used as a loading control. (D) Images derived from immunofluorescence analysis showing the protein expression of LARP1 after transfecting HEC-1A cells with control or LARP1 siRNA at 75 µM. Scale bar = 50 µM.

    Journal: bioRxiv

    Article Title: “Targeting LARP1 Enhances Carboplatin Sensitivity and Suppresses Tumor Growth in Endometrial Cancer”

    doi: 10.64898/2026.03.22.713473

    Figure Lengend Snippet: (A, B) Kaplan-Meier plots showing that LARP1 overexpression is associated with shorter overall survival (A) and progression-free interval (B) in endometrial cancer cohort (n=454). (C) Immunoblot analysis illustrating the protein expression of LARP1 after transfecting ISHI cell line with control or LARP1 siRNA at 25, 50, 75, and 100 nM. β-actin was used as a loading control. (D) Images derived from immunofluorescence analysis showing the protein expression of LARP1 after transfecting HEC-1A cells with control or LARP1 siRNA at 75 µM. Scale bar = 50 µM.

    Article Snippet: Human endometrial cancer cell lines HEC-1A and Ishikawa (ISHI) were obtained from ATCC (American Type Culture Collection, Manassas, VA, USA).

    Techniques: Over Expression, Western Blot, Expressing, Control, Derivative Assay, Immunofluorescence

    (A – D) Cell viability assay showing the effect of two different LARP1 siRNA (1 and 2) on the viability of ISHI (A, B) and HEC-1A (C, D) cell lines. One-way analysis of variance (ANOVA) was used to assess statistical significance among groups, followed by Tukey’s post hoc test for multiple pairwise comparisons. Data are presented as mean ± SD, with individual data points shown as dots. (E) Immunoblot analysis showing the protein expression of cleaved PARP1 and cleaved caspase 3 after transfection of ISHI and HEC-1A cells with control or LARP1 siRNAs. β-actin was used as a loading control.

    Journal: bioRxiv

    Article Title: “Targeting LARP1 Enhances Carboplatin Sensitivity and Suppresses Tumor Growth in Endometrial Cancer”

    doi: 10.64898/2026.03.22.713473

    Figure Lengend Snippet: (A – D) Cell viability assay showing the effect of two different LARP1 siRNA (1 and 2) on the viability of ISHI (A, B) and HEC-1A (C, D) cell lines. One-way analysis of variance (ANOVA) was used to assess statistical significance among groups, followed by Tukey’s post hoc test for multiple pairwise comparisons. Data are presented as mean ± SD, with individual data points shown as dots. (E) Immunoblot analysis showing the protein expression of cleaved PARP1 and cleaved caspase 3 after transfection of ISHI and HEC-1A cells with control or LARP1 siRNAs. β-actin was used as a loading control.

    Article Snippet: Human endometrial cancer cell lines HEC-1A and Ishikawa (ISHI) were obtained from ATCC (American Type Culture Collection, Manassas, VA, USA).

    Techniques: Viability Assay, Western Blot, Expressing, Transfection, Control

    (A, B) Immunoblot analysis showing the protein expression of LARP1 and E2F1 after transfecting ISHI (A) and HEC-1A (B) cells with control or LARP1 siRNA. β-actin was used as a loading control. (C) Images representing immunofluorescence staining of LARP1 (green) and E2F1 (red) in HEC-1A cells after transfection with control or LARP1 siRNA. DAPI was used as a counter stain. Scale bar = 50 µm.

    Journal: bioRxiv

    Article Title: “Targeting LARP1 Enhances Carboplatin Sensitivity and Suppresses Tumor Growth in Endometrial Cancer”

    doi: 10.64898/2026.03.22.713473

    Figure Lengend Snippet: (A, B) Immunoblot analysis showing the protein expression of LARP1 and E2F1 after transfecting ISHI (A) and HEC-1A (B) cells with control or LARP1 siRNA. β-actin was used as a loading control. (C) Images representing immunofluorescence staining of LARP1 (green) and E2F1 (red) in HEC-1A cells after transfection with control or LARP1 siRNA. DAPI was used as a counter stain. Scale bar = 50 µm.

    Article Snippet: Human endometrial cancer cell lines HEC-1A and Ishikawa (ISHI) were obtained from ATCC (American Type Culture Collection, Manassas, VA, USA).

    Techniques: Western Blot, Expressing, Control, Immunofluorescence, Staining, Transfection

    (A, B) MTS cell viability assay showing the effect of escalating concentration of carboplatin on the viability of ISHI (A) and HEC-1A cell lines. Sterile water was used as a vehicle control. One-way analysis of variance (ANOVA) was used to assess statistical significance among groups, followed by Tukey’s post hoc test for multiple pairwise comparisons. Data are presented as mean ± SD, with individual data points shown as dots.

    Journal: bioRxiv

    Article Title: “Targeting LARP1 Enhances Carboplatin Sensitivity and Suppresses Tumor Growth in Endometrial Cancer”

    doi: 10.64898/2026.03.22.713473

    Figure Lengend Snippet: (A, B) MTS cell viability assay showing the effect of escalating concentration of carboplatin on the viability of ISHI (A) and HEC-1A cell lines. Sterile water was used as a vehicle control. One-way analysis of variance (ANOVA) was used to assess statistical significance among groups, followed by Tukey’s post hoc test for multiple pairwise comparisons. Data are presented as mean ± SD, with individual data points shown as dots.

    Article Snippet: Human endometrial cancer cell lines HEC-1A and Ishikawa (ISHI) were obtained from ATCC (American Type Culture Collection, Manassas, VA, USA).

    Techniques: Viability Assay, Concentration Assay, Sterility, Control

    (A, C) Micrographs representing colony formation assay showing the effect of LARP1 transfection and carboplatin treatment on the clonogenic survival of ISHI (A) and HEC-1A (B) cell lines. (B, D) Quantitative analysis of clonogenic assay showing the effect of LARP1 knockdown and carboplatin treatment on the clonogenic survival of ISHI (B) and HEC-1A (D) cells. One-way analysis of variance (ANOVA) was used to assess statistical significance among groups, followed by Tukey’s post hoc test for multiple pairwise comparisons. Data are presented as mean ± SD, with individual data points shown as dots.

    Journal: bioRxiv

    Article Title: “Targeting LARP1 Enhances Carboplatin Sensitivity and Suppresses Tumor Growth in Endometrial Cancer”

    doi: 10.64898/2026.03.22.713473

    Figure Lengend Snippet: (A, C) Micrographs representing colony formation assay showing the effect of LARP1 transfection and carboplatin treatment on the clonogenic survival of ISHI (A) and HEC-1A (B) cell lines. (B, D) Quantitative analysis of clonogenic assay showing the effect of LARP1 knockdown and carboplatin treatment on the clonogenic survival of ISHI (B) and HEC-1A (D) cells. One-way analysis of variance (ANOVA) was used to assess statistical significance among groups, followed by Tukey’s post hoc test for multiple pairwise comparisons. Data are presented as mean ± SD, with individual data points shown as dots.

    Article Snippet: Human endometrial cancer cell lines HEC-1A and Ishikawa (ISHI) were obtained from ATCC (American Type Culture Collection, Manassas, VA, USA).

    Techniques: Colony Assay, Transfection, Clonogenic Assay, Knockdown